{
  "id": 18509712,
  "title": "Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down",
  "url": "https://urgent.news/2026/11/06/lilly-hims-reach-glp-1-deal-alnylam-sales-chief-to-step-down",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-06T13:13:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/lilly-hims-alnylam-boehringer-ultragenyx-sevasemten-ani-egetis/873843/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}